Why Tesla Motors, Dendreon, and Intercept Pharmaceuticals Tumbled Today

Stocks were mixed Thursday on a volatile day for the market. But these three stocks took big losses on the day. Find out why.

May 8, 2014 at 8:35PM

The stock market nixed hopes that it would rise to unprecedented highs on Thursday, but investors still fared relatively well, with the major market benchmarks delivering mixed results after giving up much larger gains earlier in the day. Yet certain stocks continued to face significant pressure to put up strong fundamental performance; on that score, Tesla Motors (NASDAQ:TSLA), Dendreon (NASDAQ:DNDN), and Intercept Pharmaceuticals (NASDAQ:ICPT) failed to deliver and were punished.

Source: Tesla Motors.

Tesla Motors fell 11% despite posting what many saw as strong first-quarter results. Revenue for the electric car-maker jumped more than 26% to $713 million, and adjusted earnings per share did better than investors had expected. Yet deliveries of Model S electric vehicles came in only marginally above Tesla's original quarterly forecast, and that disappointed investors who have become accustom to seeing Tesla crush its own past guidance in its actual report. Yet many things are going right at Tesla, as production rates climb steadily and make the company's goal of 35,000 deliveries for 2014 realistically achievable. Moreover, with its gigafactory battery-production facility starting to take shape, Tesla seems to be meeting all of its long-term goals even as its shares suffer a short-term bump in the road.


Source: Steven Depolo, Flickr.

Dendreon dropped 13% after the biotech producer of prostate cancer drug Provenge reported fresh quarterly results. Revenue climbed less than 2%, and even though Dendreon managed to cut its year-ago loss in half, Provenge sales have had to fight just to stay stable in the face of competition from rivals. Although cost-cutting moves have helped improve Dendreon's bottom line, the secret to long-term success lies with Provenge, and few investors believe the drug has much upside left. That could bode ill for the future prospects for Dendreon's stock, and several analysts followed up the company's report with downgrades.

Intercept Pharmaceuticals declined 13%, also in response to its earnings release last night. The biotech's net loss soared from the year-ago level due almost exclusively to the repricing of stock warrants, but rising research and development expenses also took a toll on profitability. Yet with all warrants having been converted into stock, Intercept Pharmaceuticals should have recorded its last noncash charge connected to the securities. With enough cash to fund operations until 2016, Intercept Pharmaceuticals is in a good position to let its treatments do the talking without fear of needing dilutive financing. The big question is whether its development-stage liver-disease treatments will make it through clinical testing and prove themselves as FDA-approved drugs at some point in the future. Although Intercept Pharmaceuticals has plenty of potential, investors still have to look critically at the company after its recent share-price surge.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Tesla Motors. The Motley Fool owns shares of Tesla Motors. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information